Literature DB >> 12088685

Neutralizing antibodies against HIV -- back in the major leagues?

Flavia Ferrantelli1, Ruth M Ruprecht.   

Abstract

The past few months have seen encouraging successes for neutralizing antibodies against HIV; human monoclonal antibodies targeting conserved HIV envelope epitopes potently neutralized primary virus isolates, including strains of different clades. In primates, passive immunization with combinations containing human monoclonal antibodies completely prevented infection, even after mucosal virus challenges. Epitopes recognized by the protective monoclonal antibodies are important determinants for protection and provide a rational basis for AIDS vaccine development.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12088685     DOI： 10.1016/s0952-7915(02)00362-x

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  28 in total

1.  Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.

Authors:  Bishnu P Nayak; Gangadhara Sailaja; Abdul M Jabbar
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

2.  Judging a virus by its cover.

Authors:  Eva Szomolanyi-Tsuda; Raymond M Welsh
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

3.  Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment.

Authors:  Laurent Gros; Hanna Dreja; Anne Laure Fiser; Marc Plays; Mireia Pelegrin; Marc Piechaczyk
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

4.  Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells.

Authors:  Vincent Holl; Maryse Peressin; Thomas Decoville; Sylvie Schmidt; Susan Zolla-Pazner; Anne-Marie Aubertin; Christiane Moog
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

Review 5.  Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience.

Authors:  Flavia Ferrantelli; Stefano Buttò; Aurelio Cafaro; Britta Wahren; Barbara Ensoli
Journal:  Springer Semin Immunopathol       Date:  2006-09-16

6.  Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

Authors:  Michael B Zwick; Richard Jensen; Sarah Church; Meng Wang; Gabriela Stiegler; Renate Kunert; Hermann Katinger; Dennis R Burton
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

7.  Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region.

Authors:  Nicholas J Mantis; Jana Palaia; Ann J Hessell; Simren Mehta; Zhiyi Zhu; Blaise Corthésy; Marian R Neutra; Dennis R Burton; Edward N Janoff
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

8.  Neutralization of HIV-1 by redirection of natural antibodies.

Authors:  Maria F Perdomo; Michael Levi; Matti Sällberg; Anders Vahlne
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-21       Impact factor: 11.205

9.  Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.

Authors:  Hongtao Zhang; Yujun Huang; Raja Fayad; Gregory T Spear; Liang Qiao
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

10.  Polyclonal immunoglobulin G from patients neutralizes human immunodeficiency virus type 1 primary isolates by binding free virions, but without interfering with an initial CD4-independent attachment of the virus to primary blood mononuclear cells.

Authors:  Renaud Burrer; Sandrine Haessig-Einius; Anne-Marie Aubertin; Christiane Moog
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.